ATE461179T1 - Hemmer der akt aktivität - Google Patents

Hemmer der akt aktivität

Info

Publication number
ATE461179T1
ATE461179T1 AT04750378T AT04750378T ATE461179T1 AT E461179 T1 ATE461179 T1 AT E461179T1 AT 04750378 T AT04750378 T AT 04750378T AT 04750378 T AT04750378 T AT 04750378T AT E461179 T1 ATE461179 T1 AT E461179T1
Authority
AT
Austria
Prior art keywords
compounds
activity inhibitor
act activity
directed
act
Prior art date
Application number
AT04750378T
Other languages
English (en)
Inventor
Mark Bilodeau
Craig Lindsley
Zhijian Zhao
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE461179T1 publication Critical patent/ATE461179T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
AT04750378T 2003-04-24 2004-04-20 Hemmer der akt aktivität ATE461179T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46512403P 2003-04-24 2003-04-24
PCT/US2004/012157 WO2004096129A2 (en) 2003-04-24 2004-04-20 Inhibitors of akt activity

Publications (1)

Publication Number Publication Date
ATE461179T1 true ATE461179T1 (de) 2010-04-15

Family

ID=33418187

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04750378T ATE461179T1 (de) 2003-04-24 2004-04-20 Hemmer der akt aktivität

Country Status (9)

Country Link
US (1) US7304063B2 (de)
EP (1) EP1620411B1 (de)
JP (1) JP4673300B2 (de)
CN (1) CN100422158C (de)
AT (1) ATE461179T1 (de)
AU (1) AU2004233826B2 (de)
CA (1) CA2522262A1 (de)
DE (1) DE602004026047D1 (de)
WO (1) WO2004096129A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579355B2 (en) * 2003-04-24 2009-08-25 Merck & Co., Inc. Inhibitors of Akt activity
CN1942465A (zh) 2004-04-09 2007-04-04 默克公司 Akt活性抑制剂
WO2005100356A1 (en) 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibitors of akt activity
EP1784175A4 (de) * 2004-08-23 2009-07-22 Merck & Co Inc Inhibitoren von akt-aktivität
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
BRPI0611717A2 (pt) 2005-06-10 2009-01-13 Merck & Co Inc composto, composiÇço farmacÊutica e uso do composto
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20090062302A1 (en) 2006-01-24 2009-03-05 Buser-Doepner Carolyn A Jak2 Tyrosine Kinase Inhibition
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
JP2010512312A (ja) * 2006-12-06 2010-04-22 メルク エンド カムパニー インコーポレーテッド Akt活性の阻害剤
US20100048912A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
MX2010013224A (es) * 2008-06-03 2010-12-21 Merck Sharp & Dohme Inhibidores de la actividad de la serina/treonina cinasa.
JP2011522048A (ja) * 2008-06-03 2011-07-28 メルク・シャープ・エンド・ドーム・コーポレイション Akt活性の阻害剤
ES2552087T3 (es) 2009-02-05 2015-11-25 Tokai Pharmaceuticals, Inc. Nuevos profármacos de inhibidores de CYP17 esteroidales/antiandrógenos
WO2010104705A1 (en) 2009-03-12 2010-09-16 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
UA109417C2 (uk) 2009-10-14 2015-08-25 Мерк Шарп Енд Доме Корп. ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ
EP2584903B1 (de) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
EP3330377A1 (de) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Durch rna-interferenz vermittelte hemmung der catenin (cadherin-assoziiertes protein)-beta-1 (ctnnb1)- genexpression mittels kurzer interferierender nukleinsäuren (sina)
KR102072631B1 (ko) 2010-08-17 2020-02-03 시르나 쎄러퓨틱스 인코퍼레이티드 짧은 간섭 핵산 (siNA)을 사용한 B형 간염 바이러스 (HBV) 유전자 발현의 RNA 간섭 매개 억제
EP2613782B1 (de) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
RU2014112320A (ru) * 2011-09-01 2015-10-10 Новартис Аг Ингибитор pi3k, предназначенный для применения для лечения рака кости или для предупреждения метастатической диссеминации первичных раковых клеток в кость
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
EP3358013B1 (de) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Sina-zusammensetzungen
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
CA2892361A1 (en) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Use of a wee1 inhibitor for treating a cancer characterized by low pkmyt1 expression levels
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
EP4066841A1 (de) 2013-03-14 2022-10-05 University of Maryland, Baltimore Mittel zur androgenrezeptor-abwärtsregelung und verwendungen davon
EP3033088A4 (de) 2013-08-12 2017-03-08 Tokai Pharmaceuticals, Inc. Biomarker zur behandlung neoplastischer störungen mit androgen-anzielenden therapien
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
KR20190140454A (ko) 2017-04-13 2019-12-19 아두로 바이오테크 홀딩스, 유럽 비.브이. 항-sirp 알파 항체
EP3706742B1 (de) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5-inhibitoren
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
EP3833668A4 (de) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. Prmt5-inhibitoren
US20210309688A1 (en) 2018-08-07 2021-10-07 Merck Sharp & Dohme Corp. Prmt5 inhibitors
BR112022012032A2 (pt) 2019-12-17 2022-09-06 Merck Sharp & Dohme Llc Inibidores de prmt5
IL297596A (en) * 2020-05-08 2022-12-01 Georgiamune Llc Modulators of akt3 and methods of using them

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020127214A1 (en) 1995-11-16 2002-09-12 Hemmings Brian Arthur RAC-protein kinase as therapeutic agent or in diagnostics
CA2241080A1 (en) 1995-12-20 1997-06-26 Medical Research Council Control of protein synthesis, and screening method for agents
JPH10265464A (ja) * 1997-03-24 1998-10-06 Sumitomo Pharmaceut Co Ltd Ldl受容体遺伝子発現増強剤
US6060491A (en) 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
IL136458A0 (en) 2000-05-30 2001-06-14 Peptor Ltd Protein kinase inhibitors
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2002307163B2 (en) * 2001-04-10 2006-06-29 Merck & Co., Inc. A method of treating cancer
AU2002252614B2 (en) 2001-04-10 2006-09-14 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
WO2002083675A2 (en) 2001-04-10 2002-10-24 Merck Sharp & Dohme Limited Inhibitors of akt activity
US20040116433A1 (en) 2002-04-08 2004-06-17 Owens Andrew Pate Inhibitors of akt activity
US6958334B2 (en) 2001-04-10 2005-10-25 Merck & Co., Inc. Inhibitors of Akt activity
MXPA04001088A (es) * 2001-08-03 2004-05-20 Vertex Pharma Derivados de pirazol como inhibidores de cinasa y uso de los mismos.
WO2003086279A2 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
AU2003226301A1 (en) * 2002-04-08 2003-10-20 Merck And Co., Inc. Method of treating cancer
JP4394961B2 (ja) 2002-04-08 2010-01-06 メルク エンド カムパニー インコーポレーテッド Akt活性の阻害剤としての融合キノキサリン誘導体
US20050130977A1 (en) 2002-04-08 2005-06-16 Lindsley Craig W. Inhibitors of akt activity
JP4394960B2 (ja) 2002-04-08 2010-01-06 メルク エンド カムパニー インコーポレーテッド Akt活性阻害薬
JP2006507299A (ja) 2002-10-30 2006-03-02 メルク エンド カムパニー インコーポレーテッド Akt活性の阻害薬
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy

Also Published As

Publication number Publication date
US20070082906A1 (en) 2007-04-12
WO2004096129A2 (en) 2004-11-11
EP1620411A2 (de) 2006-02-01
CN100422158C (zh) 2008-10-01
EP1620411B1 (de) 2010-03-17
CA2522262A1 (en) 2004-11-11
AU2004233826A1 (en) 2004-11-11
JP4673300B2 (ja) 2011-04-20
CN1809540A (zh) 2006-07-26
JP2006524253A (ja) 2006-10-26
WO2004096129A3 (en) 2005-01-20
EP1620411A4 (de) 2007-10-24
US7304063B2 (en) 2007-12-04
AU2004233826B2 (en) 2009-08-13
DE602004026047D1 (de) 2010-04-29

Similar Documents

Publication Publication Date Title
ATE461179T1 (de) Hemmer der akt aktivität
ATE446752T1 (de) Hemmer der akt aktivität
ATE512957T1 (de) Hemmer der akt aktivität
ATE503483T1 (de) Hemmer der akt aktivität
ATE499364T1 (de) Hemmer der akt aktivität
ATE400274T1 (de) Hemmstoffe der akt aktivität
WO2004096130A3 (en) Inhibitors of akt activity
WO2006036395A3 (en) Inhibitors of akt activity
WO2003086279A3 (en) Inhibitors of akt activity
CA2480800A1 (en) Inhibitors of akt activity
MXPA05013349A (es) Derivados de 2-amino-pirimidina como inhibidores de quinasa raf.
IL178675A0 (en) Monocyclic heterocycles as kinase inhibitors
DE60309848D1 (de) Purinderivate als kinaseinhibitoren
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
ATE554087T1 (de) Neue kinaseinhibitoren
HRP20050533A2 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
DK1648905T3 (da) Inhibitorer for thienopyridin- og furopyridinkinase
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
UA85087C2 (en) Monocyclic heterocycles as kinase inhibitors
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
EA200400475A1 (ru) Замещенные производные бензимидазола и их применение для лечения злокачественной опухоли
ATE507218T1 (de) Benzodiazepin-derivate als rock-kinasen hemmer
ATE527264T1 (de) Kondensierte heterozyklische verbindungen als hemmer von proteinkinasen
TW200602023A (en) Monocyclic heterocycles as kinase inhibitors
ATE540951T1 (de) Substituierte 7,8-dihydro-1h-pyrimidoä4,5- büdiazepin-4-amine als kinase inhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties